Table 2B.
Relative risk (95% Confidence Interval) of incident CKD accounting for risk factors in the REGARDS study
| Model 1 | Model 2 | Model 3 | |
|---|---|---|---|
| N=11,997 | N=10,737 | N=10,106 | |
| Age* | 1.51 (1.44, 1.59) | 1.46 (1.38, 1.55) | 1.46 (1.37, 1.55) |
| Male sex | 0.94 (0.84, 1.06) | 1.06 (0.94, 1.20) | 0.95 (0.84, 1.09) |
| Black race | 1.39 (1.24, 1.56) | 1.31 (1.15, 1.49) | 1.03 (0.90, 1.18) |
| Education ≥ High School | 0.70 (0.58, 0.84) | 0.80 (0.67, 0.96) | |
| Household Income ≥ $35,000 | 0.75 (0.65, 0.86) | 0.86 (0.75, 0.99) | |
| Stroke belt | 1.17 (1.04, 1.33) | 1.14 (1.01, 1.30) | |
| Current smoking | 1.23 (1.02, 1.48) | 1.30 (1.08, 1.57) | |
| Systolic blood pressure* | 1.16 (1.10, 1.22) | ||
| Body mass index* | 1.18 (1.11, 1.25) | ||
| Diabetes | 1.91 (1.65, 2.20) | ||
| Hyperlipidemia | 1.11 (0.97, 1.27) | ||
| Cardiovascular Disease | 1.31 (1.12, 1.52) | ||
| Log Urine ACR* | 1.30 (1.25, 1.36) |
*
per one standard deviation increase: for age 8 years, for SBP 15 mmHg, for BMI 5.8 kg/m2, for albumin-to-creatinine ratio 0.9 mg/g. Model 3 is additionally adjusted for ACEI/ARB and NSAID use.
Abbreviations: ACEi/ARB—angiotensin converting enzyme inhibitor/angiotensin II receptor blocker; NSAID—non-steroidal anti-inflammatory drug; ACR—albumin-to-creatinine ratio.